- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 54
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Macugen, Sham
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- LFG316, Sham, LFG316 Lower dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
- Conditions
- Glaucoma, Angle-closure, Primary, Acute
- Interventions
- QPI-1007 Injection, (including placebo)
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Orange, California • Pasadena, California • Houston, Texas + 1 more
- Conditions
- Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
- Interventions
- Everolimus, Ranibizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more
- Conditions
- Geographic Atrophy
- Interventions
- Vonaprument, Sham Administration
- Drug · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
- Conditions
- Retinopathy, Diabetic
- Interventions
- Aflibercept Injection, Sham injection
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- KUS121 high dose, KUS121 low dose, Sham procedure
- Drug
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Encino, California • Huntington Beach, California • Oakland, California + 8 more
- Conditions
- Macular Degeneration
- Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
- Drug · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 42
- States / cities
- Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad Pegol, Sham
- Drug
- Lead sponsor
- IVERIC bio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 96
- States / cities
- Beverly Hills, California • Campbell, California • Fresno, California + 86 more
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hagerstown, Maryland
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 58
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Arcadia, California • Torrance, California • Walnut Creek, California + 7 more
- Conditions
- Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
- Interventions
- QR-1123, Sham procedure
- Drug · Other
- Lead sponsor
- ProQR Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- EYP-1901, Sham IVT
- Drug · Other
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Oxnard, California + 33 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- UBX1325, Sham
- Drug · Other
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- PEGCETACOPLAN (APL-2)
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
- Conditions
- Open Angle Glaucoma
- Interventions
- 2.5mg ANX007, 5.0mg ANX007, Sham Procedure
- Biological · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Stanford, California